 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | Tevimbra (tislelizumab-jsgr) / BeiGene, BGB-A445 / BeiGene
Phase classification, Combination therapy, Metastases: BGB-A317-A445-101: Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Oct 8, 2024
P2, N=342, Active, not recruiting, Sponsor: BeiGene
Phase classification: P1 --> P2
- ||| BGB-A445 / BeiGene
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy: A Study of BGB-A445 in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Sep 19, 2024
P2, N=35, Active, not recruiting, Sponsor: BeiGene
Phase classification: P1 --> P2 Recruiting --> Active, not recruiting | N=100 --> 35 | Trial completion date: May 2026 --> Dec 2024 | Trial primary completion date: Jan 2026 --> Dec 2024
- || Tevimbra (tislelizumab-jsgr) / BeiGene, BGB-A445 / BeiGene
Enrollment change, Combination therapy, Metastases: BGB-A317-A445-101: Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Aug 13, 2024
P1, N=342, Active, not recruiting, Sponsor: BeiGene
Recruiting --> Active, not recruiting | N=100 --> 35 | Trial completion date: May 2026 --> Dec 2024 | Trial primary completion date: Jan 2026 --> Dec 2024 N=203 --> 342
- |||| Tevimbra (tislelizumab-jsgr) / BeiGene, Partruvix (pamiparib) / EMD Serono
Trial completion date, Trial primary completion date, Metastases: BGB-A317-290-LTE1: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (clinicaltrials.gov) - May 15, 2024
P3, N=300, Enrolling by invitation, Sponsor: BeiGene
N=203 --> 342 Trial completion date: Aug 2024 --> Dec 2026 | Trial primary completion date: Aug 2024 --> Dec 2026
- Tevimbra (tislelizumab) / BeiGene
BGB-LC-201 (NCT05635708): A phase 2, open-label, multi-arm study of tislelizumab (TIS; anti-PD-1) in combination with investigational agents +/- chemotherapy as first-line treatment for patients with locally advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC) (Section 50) - Mar 5, 2024 - Abstract #AACR2024AACR_7908;
P2
Trial completion date: Aug 2024 --> Dec 2026 | Trial primary completion date: Aug 2024 --> Dec 2026 Abstract is embargoed at this time.
- | BGB-A445 / BeiGene
Preclinical, Journal: BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation and antitumor effects in preclinical models. (Pubmed Central) - Feb 14, 2024
Furthermore, BGB-A445 demonstrated a strong combination antitumor effect with an anti-PD-1 antibody. Taken together, our findings show that BGB-A445, which does not block OX40-OX40L interaction in contrast to clinical-stage anti-OX40 antibodies, shows superior immune-stimulating effects and antitumor efficacy and thus warrants further clinical investigation.
- || Tevimbra (tislelizumab-jsgr) / BeiGene, BGB-A445 / BeiGene
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, Metastases: BGB-A317-A445-101: Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Jan 12, 2024
P1, N=203, Active, not recruiting, Sponsor: BeiGene
Taken together, our findings show that BGB-A445, which does not block OX40-OX40L interaction in contrast to clinical-stage anti-OX40 antibodies, shows superior immune-stimulating effects and antitumor efficacy and thus warrants further clinical investigation. Recruiting --> Active, not recruiting | Trial completion date: Jul 2025 --> Sep 2024 | Trial primary completion date: May 2025 --> Sep 2024
- ||| Tevimbra (tislelizumab-jsgr) / BeiGene
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases: BGB-LC-201: A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jan 7, 2024
P2, N=400, Recruiting, Sponsor: BeiGene
Recruiting --> Active, not recruiting | Trial completion date: Jul 2025 --> Sep 2024 | Trial primary completion date: May 2025 --> Sep 2024 N=200 --> 400
- ||| BGB-A445 / BeiGene
Enrollment open, Combination therapy: A Study of BGB-A445 in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Nov 8, 2023
P2, N=100, Recruiting, Sponsor: BeiGene
N=200 --> 400 Not yet recruiting --> Recruiting
- |||| BGB-A445 / BeiGene
New P2 trial, Combination therapy: A Study of BGB-A445 in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Sep 8, 2023
P2, N=100, Not yet recruiting, Sponsor: BeiGene
- || Tevimbra (tislelizumab-jsgr) / BeiGene, BGB-A445 / BeiGene
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases: BGB-A317-A445-101: Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Jun 12, 2023
P1, N=250, Recruiting, Sponsor: BeiGene
Not yet recruiting --> Recruiting N=360 --> 250 | Trial completion date: Sep 2024 --> Jul 2025 | Trial primary completion date: Jun 2024 --> May 2025
- ||| Tevimbra (tislelizumab-jsgr) / BeiGene
Enrollment open, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases: BGB-LC-201: A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer (clinicaltrials.gov) - May 23, 2023
P2, N=200, Recruiting, Sponsor: BeiGene
N=360 --> 250 | Trial completion date: Sep 2024 --> Jul 2025 | Trial primary completion date: Jun 2024 --> May 2025 Not yet recruiting --> Recruiting | N=300 --> 200 | Trial completion date: Nov 2025 --> Jul 2025 | Trial primary completion date: Nov 2025 --> Jul 2025
- Baizean (tislelizumab) / BeiGene, Novartis, BGB-A445 / BeiGene
A phase 1 study of the OX40 agonist, BGB-A445, with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors. (On Demand | Hall A; Poster Bd # 416) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2342;
P1
The dose expansion part of the study is ongoing in pts with non-small cell lung cancer and head and neck squamous cell carcinoma. Clinical trial information: NCT04215978.
- ||| Tevimbra (tislelizumab) / BeiGene, BGB-A445 / BeiGene
Enrollment open, Combination therapy, Metastases: A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors. (clinicaltrials.gov) - Apr 25, 2023
P1b/2, N=180, Recruiting, Sponsor: BeiGene
Clinical trial information: NCT04215978. Not yet recruiting --> Recruiting
- |||| Tevimbra (tislelizumab-jsgr) / BeiGene, Partruvix (pamiparib) / EMD Serono
Trial completion date, Trial primary completion date, Metastases: BGB-A317-290-LTE1: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (clinicaltrials.gov) - Jan 11, 2023
P3, N=300, Enrolling by invitation, Sponsor: BeiGene
Not yet recruiting --> Recruiting Trial completion date: Dec 2022 --> Aug 2024 | Trial primary completion date: Dec 2022 --> Aug 2024
- ||||| Tevimbra (tislelizumab-jsgr) / BeiGene
New P2 trial, Combination therapy, Metastases: BGB-LC-201: A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Dec 2, 2022
P2, N=300, Not yet recruiting, Sponsor: BeiGene
- || Tevimbra (tislelizumab-jsgr) / BeiGene, BGB-A445 / BeiGene
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases: BGB-A317-A445-101: Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Jun 22, 2022
P1, N=331, Recruiting, Sponsor: BeiGene
Trial completion date: Dec 2022 --> Aug 2024 | Trial primary completion date: Dec 2022 --> Aug 2024 N=68 --> 331 | Trial completion date: Oct 2022 --> Sep 2024 | Trial primary completion date: Oct 2022 --> Jun 2024
- |||| Tevimbra (tislelizumab-jsgr) / BeiGene, Partruvix (pamiparib) / EMD Serono
Trial completion date, Trial primary completion date, Metastases: BGB-A317-290-LTE1: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (clinicaltrials.gov) - Mar 8, 2022
P3, N=300, Enrolling by invitation, Sponsor: BeiGene
N=68 --> 331 | Trial completion date: Oct 2022 --> Sep 2024 | Trial primary completion date: Oct 2022 --> Jun 2024 Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
- BGB-A445 / BeiGene
[VIRTUAL] A differentiated anti-OX40 agonist BGB-A445 does not block OX40-OX40L interaction and reveals remarkable anti-tumor efficacy in preclinical models () - Oct 14, 2020 - Abstract #SITC2020SITC_1722;
Conclusions In conclusion, differentiated from current clinical stage anti-OX40 antibodies, BGB-A445 is an agonistic antibody that does not block the OX40-OX40L interaction. Both in vitro and in vivo results demonstrated that BGB-A445 has remarkable immune stimulating effect and anti-tumor efficacy either as a single agent or in combination with anti-PD-1 therapy, thus warranting further clinical investigation.
- BGB-A445 / BeiGene
[VIRTUAL] A differentiated anti-OX40 agonist BGB-A445 does not block OX40-OX40L interaction and reveals remarkable anti-tumor efficacy in preclinical models () - Oct 14, 2020 - Abstract #SITC2020SITC_987;
Conclusions In conclusion, differentiated from current clinical stage anti-OX40 antibodies, BGB-A445 is an agonistic antibody that does not block the OX40-OX40L interaction. Both in vitro and in vivo results demonstrated that BGB-A445 has remarkable immune stimulating effect and anti-tumor efficacy either as a single agent or in combination with anti-PD-1 therapy, thus warranting further clinical investigation.
- |||| Tevimbra (tislelizumab-jsgr) / BeiGene, Partruvix (pamiparib) / EMD Serono
Trial completion date, Trial primary completion date, Metastases: BGB-A317-290-LTE1: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (clinicaltrials.gov) - Aug 12, 2020
P3, N=300, Enrolling by invitation, Sponsor: BeiGene
Both in vitro and in vivo results demonstrated that BGB-A445 has remarkable immune stimulating effect and anti-tumor efficacy either as a single agent or in combination with anti-PD-1 therapy, thus warranting further clinical investigation. Trial completion date: Dec 2024 --> Dec 2021 | Trial primary completion date: Dec 2024 --> Dec 2021
- ||| Tevimbra (tislelizumab-jsgr) / BeiGene, BGB-A445 / BeiGene
Enrollment open, Combination therapy, Metastases: BGB-A317-A445-101: Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Mar 9, 2020
P1, N=68, Recruiting, Sponsor: BeiGene
Trial completion date: Dec 2024 --> Dec 2021 | Trial primary completion date: Dec 2024 --> Dec 2021 Not yet recruiting --> Recruiting
- ||| Tevimbra (tislelizumab-jsgr) / BeiGene, BGB-A445 / BeiGene
New P1 trial, Combination therapy, Metastases: BGB-A317-A445-101: Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Jan 2, 2020
P1, N=68, Not yet recruiting, Sponsor: BeiGene
- |||||| Tevimbra (tislelizumab-jsgr) / BeiGene, Partruvix (pamiparib) / EMD Serono
Enrollment open, Metastases: BGB-A317-290-LTE1: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (clinicaltrials.gov) - Dec 23, 2019
P3, N=300, Enrolling by invitation, Sponsor: BeiGene
Not yet recruiting --> Recruiting Not yet recruiting --> Enrolling by invitation
- |||||||||| Tevimbra (tislelizumab-jsgr) / BeiGene, Partruvix (pamiparib) / EMD Serono
New P3 trial, Metastases: BGB-A317-290-LTE1: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (clinicaltrials.gov) - Nov 15, 2019
P3, N=300, Not yet recruiting, Sponsor: BeiGene